24 Nov

4DMedical to present at NWR Virtual Healthcare Day

ASX announcement ASX:4DX The future of lung health Melbourne 5/468 St. Kilda Rd, Melbourne, Victoria, 3004 Los Angeles 21600 Oxnard St #300, Woodland Hills, 91367, CA 4DMedical L imi t e d ABN: 31 161 684 831 Email: info@4DMedical.com 1 Tel: +61 (3) 9545 5940 Tel: +1 (818) 794 - 6467 www.4 DM edical.com 4DMedical to present at NWR Virtual Healthcare Day 2 4 November 2021 4DMedical Limited (ASX:4DX, “ 4DMedical ” , or the “ Company ” ), a medical technology company focused on commercialising its FDA - cleared and TGA - approved respiratory imaging platform, is pleased to announce that Managing Director and CEO Dr Andreas Fouras will be presenting at the NWR Virtual Healthcare Day at 10:5 0 a m AEDT today, Wednesday 24 November 2021. Investors can register for the session at the following link: https://us02web.zoom.us/webinar/register/WN_OhgvD9_oTIaRrJMVBLys7g After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link above. Investors are invited to submit questions prio r to the webinar to matt@nwrcommunications.com.au For more information on the conference click here: https://nwrconference.webflow.io/ – ENDS – Authorised by Andreas Fouras, CEO . Contacts Corporate Charlene Stahr Company Secretary companysecretary@4dmedical.com Investor Simon Hinsley + 61 401 809 653 shinsley@4dmedical.com Media Matthew Wright + 61 451 896 420 matt@nwrcommunications.com.au About 4DMedical Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX). 4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory di agnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in prov iding sensitive, early diagnosis, and to monitor changes over time. Our Software - as - a - Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods. Respiratory diagnos tics is a US$31 billion per annum global industry. Through its technology , 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctor s and patients about lung function. Better information means better decisions, and better outcomes.

More from 4DMedical Limited

Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from 4DMedical Limited (ASX:4DX) when you join Listcorp.